| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Baker Medical Research Institute and Latrobe University (J.D.C.), Melbourne 8008; and Novogen Ltd. (L.W.), North Ryde 2113, Australia
Address all correspondence and requests for reprints to: Dr. P. J. Nestel, Baker Medical Research Institute, P.O. Box 6492, Melbourne 8008, Australia.
 |
Abstract |
|---|
 Top Abstract IntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
An initial 3- to 4-week run-in period and a 5-week placebo period were followed by two 5-week periods of active treatment with 40 mg and then 80 mg isoflavones derived from red clover containing genistein, daidzein, biochanin, and formononetin in 14 and 13 women, respectively, with 3 others serving as placebo controls throughout. Arterial compliance, measured by ultrasound as a pressure (carotid artery) and volume (outflow into aorta) relationship, was determined after each period; plasma lipids were measured twice during each period. Urinary output of isoflavones was also determined.
Arterial compliance rose by 23% relative to that during the placebo period with the 80-mg isoflavone dose and slightly less with the 40-mg dose (mean ± SEM: placebo, 19.7 ± 1.5; 40 mg, 23.7 ± 0.7; 80 mg, 24.4 ± 1.4). In the three women receiving continuous placebo, compliance was 16 ± 2.2, similar to that during the run-in period for the remaining subjects (17 ± 2.1). ANOVA showed a significant (P = < 0.001) difference between treatments; by Bonferroni multiple comparisons and by paired t test, differences were significant between placebo and 40- and 80-mg isoflavone doses (by paired t test: P = 0.039 for placebo vs. 40 mg; P = 0.018 for placebo vs. 80 mg). Plasma lipids were not significantly affected.
An important cardiovascular risk factor, arterial compliance, which diminishes with menopause, was significantly improved with red clover isoflavones. As diminished compliance leads to systolic hypertension and may increase left ventricular work, the findings indicate a potential new therapeutic approach for improved cardiovascular function after menopause.
|
Introduction |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
Similar isoflavones are present in other plants, and red clover contains, in addition to genistein and diadzein, which are present in soybean, the methylated forms biochanin and formononetin. We tested an isolated, purified extract of red clover isoflavones on arterial compliance in 17 menopausal women. As impaired compliance has been shown to be associated with aging, menopause, hypertension, and possibly hyperlipidemia (5, 8) and to probably be partly responsible for systolic hypertension in elderly people (9), supplementation with red clover isoflavones was investigated as a possible therapeutic intervention.
|
Subjects and Methods |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
Women were invited through newspaper advertisements to take part in a clinical trial of a purified red clover isoflavone extract (Novogen Pty. Ltd., North Ryde, Australia) that might reduce measurable cardiovascular risk. Respondents had been clearly postmenopausal for at least the preceding year. Objective measurements of FSH confirmed menopausal status.
Exclusion criteria were age more than 70 yr; hormone replacement
therapy, which several women discontinued for at least 6 weeks
beforehand; and supplements such as evening primrose oil and vitamin E,
which were also stopped 4–6 weeks before the study. Inclusion criteria
also required a FSH level above 40 and a plasma cholesterol level at
recruitment between 5–7 mmol/L. No subject took any regular medication
that might have affected plasma lipids or cardiovascular function.
Smoking and drinking more than 14 standard alcoholic drinks weekly and
body mass index greater than 32 were other exclusion criteria. Physical
examination showed that they were free of apparent cardiovascular
disease. Relevant details are shown in Table 1
. The trial was approved by Alfred
Hospital human ethics committee and was carefully explained to obtain
informed consent.
|
The design comprised a run-in period that averaged 3 weeks, during which the women became familiar with dietary principles, including avoidance of legumes, identifying fat content of foods, and maintaining a regular food pattern with a target of no more than 30% energy from fat. The women received placebo tablets during this phase.
The women were then randomized into an active intervention group or a placebo group (although only every fifth woman was randomized to take placebo throughout as an index of changes over time). The remaining women were assigned to take 2 placebo tablets/day for 5 weeks and then 1 Promensil (Novogen; 40 mg isoflavone) and 1 placebo tablet daily for a further 5 weeks and then 2 80-mg isoflavone tablets daily for a final 5 weeks. Of 26 women enrolled, only 19 completed the study with respect to the plasma lipid investigations, and only 17 underwent measurements of arterial compliance to the end of the first intervention period. The high dropout rate was due to intercurrent illnesses and changed geographic circumstances and was higher during the placebo phases than during the intervention phases due to intolerable menopausal symptoms requiring hormone replacement treatment. Thus, only 3 women instead of 5 originally randomized to placebo throughout the study completed the trial. The study was carried out double blind, with an external monitor supervising the trial.
The background diet constraints were applied throughout and were supervised closely by a dietitian. Subjects were encouraged to compose their diets of whole grain cereal foods, fruit and vegetables, low fat dairy products, fish, lean and skinless poultry, as well as lean meat. Soy-based food products and leguminous vegetables were omitted. Subjects kept 3-day food records during each phase of the trial. A normal exercise routine was encouraged. The subjects attended the clinic every 2 weeks, when either tablets were dispensed or compliance with diet and medication was checked. Twenty-four-hour urine samples were collected after the designated active and placebo periods for measurements of isoflavonoid excretion to monitor absorption.
Isoflavone supplements
The standardized isoflavone supplement used was a proprietary product called Promensil (Novogen), prepared from red clover extract containing 40 mg/tablet total isoflavones comprising four primary isoflavones: genistein, 4 mg; daidzein, 3.5 mg; and their methylated precursors biochanin, 24.5 mg; and formononetin, 8.0 mg, present as hydrolyzed aglycones. The placebo tablet contained excipients without isoflavones and was similar in taste and appearance.
Laboratory measurements
Measurements were made at the end of each period, i.e. run-in (baseline diet only), placebo, and two active periods. Blood for plasma lipid measurements was collected on 2 consecutive days. The women taking placebo throughout were tested at equivalent time points.
The determination of systemic arterial compliance, which measures the elasticity of the main conduit arteries and which included frequent automated arterial pressure measurements, was carried out near the end of each period.
Systemic arterial compliance
Systemic arterial compliance (SAC) was estimated using the area method of Liu et al. (10), which requires measurement of volumetric blood flow and associated driving pressure to derive an estimated compliance over the total arterial system according to the formula: SAC = Ad[R(Ps - Pd)], where Ad is the area under the blood pressure diastolic decay curve from end systole to end diastole, R is the total peripheral resistance, Ps is the end-systolic blood pressure, and Pd is the end-diastolic blood pressure. Both aortic flow, measured with a flow velocimeter over the suprasternal notch, and pressure signals, measured by applanation tonometry over the right carotid artery, were digitized at 4 MHz using a analog to digital conversion board. Data were acquired and analyzed with purpose-written software (J. D. Cameron). The computation of compliance proceeds automatically; the observer is required only to ensure stable baselines and consistently reproducible pressure-flow traces. The methodology has been described fully in our previous publications (5, 11).
Plasma lipids
Plasma was separated from chilled blood samples and frozen at -80 C. Measurements were carried out in batches for plasma glucose, cholesterol, and triglyceride by enzymatic kits on a Cobas-Bio automated analyzer (Roche, Basel, Switzerland). High density lipoprotein (HDL) cholesterol was separated from plasma by selective precipitation of other lipoproteins.
Isoflavone content
Isoflavone excretion in urine was estimated by assay of the total isoflavone content using high performance liquid chromatographic analysis (performed by Novogen) of an aliquot of a 24-h urine collection and correcting for urine volume to obtain the total excretion value.
Statistical analysis
The active treatment group was analyzed initially by one-way repeated measures ANOVA, corrected subsequently by Bonferroni correction for multiple comparisons, and analyzed finally by paired t test between the various interventions (run-in, placebo, and 40- and 80-mg doses). As only three women completed the placebo-only arm of the study, their data were not subjected to statistical analysis.
|
Results |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
Four intervention periods comprised an initial run-in period
during which placebo tablets were taken, averaging 3 weeks, and then
sequentially placebo, 40 mg isoflavone, and 80 mg isoflavone periods,
each of 5-week duration. Fourteen women completed the first 3 phases,
and 13 women completed the entire study; 3 additional women took only
placebo tablets throughout. The results include the run-in data as a
reference point, but interpretation and conclusions will be limited to
placebo vs. active groups. The data have been examined in
the first instance for effects of time and order of treatment,
including possible carry-over. None of these was found to be a
confounder. The findings are summarized in Table 2.
|
By one-way repeated measures of variance that had a power of 0.9 to detect a less than 5% difference, a significant difference between treatments in the active stream was demonstrated (P < 0.001); this was attributable to a significant increase in compliance with both the 40- and 80-mg isoflavone doses compared with placebo (both P < 0.05). By paired t test, for placebo vs. 40 mg, the difference was significant at P = 0.039; and for placebo vs. 80 mg, the difference was significant at P = 0.018. Arterial compliance between the two treatment phases was not significantly different, nor was the difference between placebo and run-in periods.
Importantly the arterial compliance values correlated for individuals across placebo and the two isoflavone periods (between placebo and 40 mg: r = 0.60; P = 0.032; between placebo and 80 mg: r = 0.63; P = 0.021). This supports the homogeneity of the values across time.
Arterial pressures did not change significantly over time; mean
pressures during the four periods are shown in Table 2
(the higher mean
value for the 80-mg dose is attributable to a single subject whose
pressure rose by 15 mm Hg). Plasma lipoprotein levels did not change
significantly with treatment (Table 2), although there was a downward
trend in LDL cholesterol and an upward trend in HDL cholesterol, giving
an approximately 10% reduction in the LDL/HDL cholesterol ratio
between placebo and treatment values, which, however, failed to reach
statistical significance. The mean body mass index remained virtually
unchanged during the trial. Thus, some of the biological variables that
might influence arterial compliance did not change, and this
strengthens the conclusion that the improvement in compliance was due
primarily to the isoflavone supplements.
Urinary isoflavones showed satisfactory absorption, with a
dose-dependent increase in urinary isoflavone output (Table 3). Subjects receiving placebo throughout
the study showed low isoflavone excretion, although there was a small
increase at the end due to an elevated value in one subject. Absorption
was at least 25% and was consistent across the 10-week intervention
period.
|
|
Discussion |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
The order of increase in arterial compliance resembled that observed in
this institute with estrogen replacement therapy in menopausal women
(16). We recently showed that 5-week consumption of flaxseed oil, rich
in the n-3 fatty acid, 
-linolenic acid, increased arterial
compliance significantly over that measured when subjects ate a
saturated fatty acid-rich diet (17) or when overweight women lost
weight (18).
Thus, systemic arterial compliance is susceptible to significant improvement within weeks. As the increasing stiffness of the large conduit arteries, especially the descending aorta, is believed to contribute to cardiovascular disease, including systolic hypertension, coronary artery insufficiency, and left ventricular dysfunction (19), the demonstration of reversibility points to functional causal components. Because endothelial events influence the smooth muscle layer in the artery and because endothelial function is rapidly modifiable, we favor a mechanistic change, based on endothelium-related arterial relaxation. Estrogen supplementation has been reported to raise flow-mediated dilation in the brachial artery, a conduit artery, in menopausal women (20).
The effect of dietary legumes on plasma lipids has been controversial. Several well controlled comparisons of soy protein vs. animal protein (generally casein) have shown minimal if any differences (13), yet other studies have shown impressive cholesterol lowering (13), raising the question, as yet unanswered, of whether differences in some active components account for this discrepancy. The present study confirms our previous finding (5) of failure to reduce plasma LDL cholesterol with the isoflavones genistein and daidzein from soybeans. Nevertheless, the LDL/HDL cholesterol ratio declined by about 10%, as both lipids changed in opposing directions. Although not significant in the present small group of women, the change does suggest potential benefit, as demonstrated for whole soy protein.
Although we did not specifically document menopausal symptomatology, two of five women in the placebo-only stream withdrew, and several others withdrew early from the active stream before the treatment phases. Several women cited a return of intolerable hot flashing that required resumption of hormone replacement therapy. The study was placebo controlled and carried out double blind. However, it was not a cross-over design, so that placebo preceded treatment in the active stream. We had intended to monitor this through a smaller group of placebo-only women (every fifth subject randomized) in whom mean arterial compliance changed minimally and was similar to the mean values obtained in the active stream during their run-in and placebo periods. It is therefore most unlikely that the significant increments in arterial compliance that occurred during the 10 weeks on the two doses of isoflavone (the responses to the 40- and 80-mg doses were similar) were not due to the treatment. Interestingly, a recent report in menopausal women treated with long term conventional hormone replacement showed a 24% greater value in arterial compliance (using the technique employed in the present study) compared with women not taking replacement hormones (21), a change that is almost identical to that with isoflavones in the present study.
As decreasing arterial compliance is a common cause of systolic hypertension and may lead to left ventricular dysfunction (19), it is of interest that recent trials have shown decreased compliance in subjects with clinical coronary artery disease compared with controls (22, 23).
|
Acknowledgments |
|---|
|
Footnotes |
|---|
Received August 13, 1998.
Revised December 10, 1998.
Accepted December 15, 1998.
|
References |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
 |
|
 |
|
  A. A Thorp, P. R. Howe, T. A Mori, A. M Coates, J. D Buckley, J. Hodgson, J. Mansour, and B. J Meyer Soy food consumption does not lower LDL cholesterol in either equol or nonequol producers Am. J. Clinical Nutrition, August 1, 2008; 88(2): 298 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gonzalez, V. Jayagopal, E. S. Kilpatrick, T. Chapman, and S. L. Atkin Effects of Isoflavone Dietary Supplementation on Cardiovascular Risk Factors in Type 2 Diabetes Diabetes Care, July 1, 2007; 30(7): 1871 - 1873. [Full Text] [PDF]
|
|
|
|
 |
|
 F. K. Welty, K. S. Lee, N. S. Lew, and J.-R. Zhou Effect of Soy Nuts on Blood Pressure and Lipid Levels in Hypertensive, Prehypertensive, and Normotensive Postmenopausal Women Arch Intern Med, May 28, 2007; 167(10): 1060 - 1067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Michaud, J. P. Karpinski, K. L. Jones, and J. Espirito Dietary supplements in patients with cancer: Risks and key concepts, part 2 Am. J. Health Syst. Pharm., March 1, 2007; 64(5): 467 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Erdman Jr., D. Balentine, L. Arab, G. Beecher, J. T. Dwyer, J. Folts, J. Harnly, P. Hollman, C. L. Keen, G. Mazza, et al. Flavonoids and Heart Health: Proceedings of the ILSI North America Flavonoids Workshop, May 31-June 1, 2005, Washington, DC J. Nutr., March 1, 2007; 137(3): 718S - 737S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Teede, D. Giannopoulos, F. S. Dalais, J. Hodgson, and B. P. McGrath Randomised, Controlled, Cross-Over Trial of Soy Protein with Isoflavones on Blood Pressure and Arterial Function in Hypertensive Subjects J. Am. Coll. Nutr., December 1, 2006; 25(6): 533 - 540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Dewell, P. L. W. Hollenbeck, and C. B. Hollenbeck A Critical Evaluation of the Role of Soy Protein and Isoflavone Supplementation in the Control of Plasma Cholesterol Concentrations J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 772 - 780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Douglas, J. A. Armitage, P. D. Taylor, J. R. Lawson, G. E. Mann, and L. Poston Cardiovascular consequences of life-long exposure to dietary isoflavones in the rat J. Physiol., March 1, 2006; 571(2): 477 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hallund, G. Ravn-Haren, S. Bugel, T. Tholstrup, and I. Tetens A Lignan Complex Isolated from Flaxseed Does Not Affect Plasma Lipid Concentrations or Antioxidant Capacity in Healthy Postmenopausal Women J. Nutr., January 1, 2006; 136(1): 112 - 116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ma, D. Chiriboga, B. C. Olendzki, R. Nicolosi, P. A. Merriam, and I. S. Ockene Effect of Soy Protein Containing Isoflavones on Blood Lipids in Moderately Hypercholesterolemic Adults: A Randomized Controlled Trial J. Am. Coll. Nutr., August 1, 2005; 24(4): 275 - 285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Williamson and C. Manach Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies Am. J. Clinical Nutrition, January 1, 2005; 81(1): 243S - 255S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-G. Zhuo, M. K. Melby, and S. Watanabe Soy Isoflavone Intake Lowers Serum LDL Cholesterol: A Meta-Analysis of 8 Randomized Controlled Trials in Humans J. Nutr., September 1, 2004; 134(9): 2395 - 2400. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kreijkamp-Kaspers, L. Kok, D. E. Grobbee, E. H. F. de Haan, A. Aleman, J. W. Lampe, and Y. T. van der Schouw Effect of Soy Protein Containing Isoflavones on Cognitive Function, Bone Mineral Density, and Plasma Lipids in Postmenopausal Women: A Randomized Controlled Trial JAMA, July 7, 2004; 292(1): 65 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. G. Sobey, J. M. Weiler, M. Boujaoude, and O. L. Woodman Effect of Short-Term Phytoestrogen Treatment in Male Rats on Nitric Oxide-Mediated Responses of Carotid and Cerebral Arteries: Comparison with 17{beta}-Estradiol J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 135 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Piersen Phytoestrogens in Botanical Dietary Supplements: Implications for Cancer Integr Cancer Ther, June 1, 2003; 2(2): 120 - 138. [Abstract] [PDF]
|
|
|
|
 |
|
 H. J. Teede, B. P. McGrath, L. DeSilva, M. Cehun, A. Fassoulakis, and P. J. Nestel Isoflavones Reduce Arterial Stiffness: A Placebo-Controlled Study in Men and Postmenopausal Women Arterioscler. Thromb. Vasc. Biol., June 1, 2003; 23(6): 1066 - 1071. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Kurzer Phytoestrogen Supplement Use by Women J. Nutr., June 1, 2003; 133(6): 1983S - 1986. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Nestel Role of Soy Protein in Cholesterol-Lowering: How Good Is It? Arterioscler. Thromb. Vasc. Biol., November 1, 2002; 22(11): 1743 - 1744. [Full Text] [PDF]
|
|
|
|
|
|
A. H. Lichtenstein, S. M. Jalbert, H. Adlercreutz, B. R. Goldin, H. Rasmussen, E. J. Schaefer, and L. M. Ausman Lipoprotein Response to Diets High in Soy or Animal Protein With and Without Isoflavones in Moderately Hypercholesterolemic Subjects Arterioscler. Thromb. Vasc. Biol., November 1, 2002; 22(11): 1852 - 1858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A.J.M. Kerckhoffs, F. Brouns, G. Hornstra, and R. P. Mensink Effects on the Human Serum Lipoprotein Profile of {beta}-Glucan, Soy Protein and Isoflavones, Plant Sterols and Stanols, Garlic and Tocotrienols J. Nutr., September 1, 2002; 132(9): 2494 - 2505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Anthony Phytoestrogens and Cardiovascular Disease: Where's the Meat? Arterioscler. Thromb. Vasc. Biol., August 1, 2002; 22(8): 1245 - 1247. [Full Text] [PDF]
|
|
|
|
|
|
N. Tsunoda, S. Pomeroy, and P. Nestel Absorption in Humans of Isoflavones from Soy and Red Clover Is Similar J. Nutr., August 1, 2002; 132(8): 2199 - 2201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. T. van der Schouw, A. Pijpe, C. E.I. Lebrun, M. L. Bots, P. H.M. Peeters, W. A. van Staveren, S. W.J. Lamberts, and D. E. Grobbee Higher Usual Dietary Intake of Phytoestrogens Is Associated With Lower Aortic Stiffness in Postmenopausal Women Arterioscler. Thromb. Vasc. Biol., August 1, 2002; 22(8): 1316 - 1322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Dewell, C. Hollenbeck, and B. Bruce Authors' Response: Soy Supplement--Why Is the Effect So Elusive? J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3508 - 3509. [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Han, J. M. Soares Jr, M. A. Haidar, G. R. de Lima, and E. C. Baracat Benefits of Soy Isoflavone Therapeutic Regimen on Menopausal Symptoms Obstet. Gynecol., March 1, 2002; 99(3): 389 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J Husband and M. de Lemos Phytoestrogens and menopause BMJ, January 5, 2002; 324(7328): 52 - 52. [Full Text]
|
|
|
|
|
|
A. Dewell, C. B. Hollenbeck, and B. Bruce The Effects of Soy-Derived Phytoestrogens on Serum Lipids and Lipoproteins in Moderately Hypercholesterolemic Postmenopausal Women J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 118 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Burdette, J. Liu, D. Lantvit, E. Lim, N. Booth, K. P. L. Bhat, S. Hedayat, R. B. Van Breemen, A. I. Constantinou, J. M. Pezzuto, et al. Trifolium pratense (Red Clover) Exhibits Estrogenic Effects In Vivo in Ovariectomized Sprague-Dawley Rats J. Nutr., January 1, 2002; 132(1): 27 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J Nestel How good is chocolate? Am. J. Clinical Nutrition, November 1, 2001; 74(5): 563 - 564. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Messina and C. L. Loprinzi Soy for Breast Cancer Survivors: A Critical Review of the Literature J. Nutr., November 1, 2001; 131(11): 3095S - 3108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. D. R. Setchell Soy Isoflavones--Benefits and Risks from Nature's Selective Estrogen Receptor Modulators (SERMs) J. Am. Coll. Nutr., October 1, 2001; 20(90005): 354S - 362. [Abstract] [Full Text]
|
|
|
|
|
|
S. B. Dent, C. T. Peterson, L. D. Brace, J. H. Swain, M. B. Reddy, K. B. Hanson, J. G. Robinson, and D. L. Alekel Soy Protein Intake by Perimenopausal Women Does Not Affect Circulating Lipids and Lipoproteins or Coagulation and Fibrinolytic Factors J. Nutr., September 1, 2001; 131(9): 2280 - 2287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Teede, F. S. Dalais, D. Kotsopoulos, Y.-L. Liang, S. Davis, and B. P. McGrath Dietary Soy Has Both Beneficial and Potentially Adverse Cardiovascular Effects: A Placebo-Controlled Study in Men and Postmenopausal Women J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3053 - 3060. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Burow, S. M. Boue, B. M. Collins-Burow, L. I. Melnik, B. N. Duong, C. H. Carter-Wientjes, S. Li, T. E. Wiese, T. E. Cleveland, and J. A. McLachlan Phytochemical Glyceollins, Isolated from Soy, Mediate Antihormonal Effects through Estrogen Receptor {{alpha}} and {beta} J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1750 - 1758. [Abstract] [Full Text]
|
|
|
|
|
|
K. D. R. Setchell, N. M. Brown, P. Desai, L. Zimmer-Nechemias, B. E. Wolfe, W. T. Brashear, A. S. Kirschner, A. Cassidy, and J. E. Heubi Bioavailability of Pure Isoflavones in Healthy Humans and Analysis of Commercial Soy Isoflavone Supplements J. Nutr., April 1, 2001; 131(4): 1362S - 1375. [Abstract] [Full Text]
|
|
|
|
|
|
K. E Wangen, A. M Duncan, X. Xu, and M. S Kurzer Soy isoflavones improve plasma lipids in normocholesterolemic and mildly hypercholesterolemic postmenopausal women Am. J. Clinical Nutrition, February 1, 2001; 73(2): 225 - 231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Poster Presentation Abstracts J. Nutr., |
